Pilocytic astrocytomas of the diencephalon with onset of signs and symptoms during the first year of life are reported in 7 boys and 5 girls. Failure to thrive was the initial manifestation in 5 infants. In 2 of them a Russel syndrome emerged. The growth rate of the tumors was slow. One child survived without treatment for 2.5 years. The survival time of the treated children ranged from 7 months to 6 years and 4 months. All children died. No obvious indications of neurofibromatosis were found. All tumors infiltrated and destroyed the hypothalamus. In addition, the tumor infiltrated the optic chiasm in 3 cases and extended into the optic nerves in 2 of them. Most of the astrocytomas were large. Their maximal diameter exceeded 10 cm in 2 children. All were pilocytic astrocytomas grade 1. The grade of malignancy was the same in recurrences as in the initial operative material. Rosenthal fibres were uncommon. It is concluded that diencephalic pilocytic astrocytomas biologically and morphologically resemble most of the pilocytic astrocytomas occurring in early life in other parts of the brain. There is, therefore, no justification for regarding them as a separate tumor entity.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pilocytic astrocytomas
16
astrocytomas
5
[diencephalic pilocytic
4
pilocytic astrocytoma
4
astrocytoma clinical
4
clinical onset
4
onset infancy
4
infancy biological
4
biological behavior
4
behavior pathomorphological
4

Similar Publications

Low-grade gliomas and reactive piloid gliosis can present with overlapping features on conventional histology. Given the large implications for patient treatment, there is a need for effective methods to discriminate these morphologically similar but clinically distinct entities. Using routinely available stains, we hypothesize that a limited panel including SOX10, p16, and cyclin D1 may be useful in differentiating mitogen-activated protein (MAP) kinase-activated low-grade gliomas from piloid gliosis.

View Article and Find Full Text PDF

Target populationAdults with imaging suggestive of a WHO grade II diffuse gliomas (oligodendrogliomas or astrocytomas)QuestionIn adults with imaging suggestive of a WHO grade II diffuse gliomas (oligodendrogliomas or astrocytomas), does surgical resection improve overall survival compared to observation or biopsy?Updated Recommendation from the Prior Version of These Guidelines:Level III: In adults with imaging suggestive of a WHO grade II diffuse gliomas (oligodendrogliomas or astrocytomas), surgical resection is suggested over observation or biopsy to improve overall survival.Question Q2In adults with imaging suggestive of a WHO grade II diffuse gliomas (oligodendrogliomas or astrocytomas), does maximal surgical resection improve progression free survival (PFS) and overall survival (OS) compared to subtotal resection/biopsy?Unchanged Recommendations from the Prior Version of These GuidelinesLevel II It is recommended that GTR or STR be accomplished instead of biopsy alone when safe and feasible so as to decrease the frequency of tumor progression recognizing that the rate of progression after GTR is fairly high.Level III Greater extent of resection can improve OS in WHO grade II diffuse gliomas patients.

View Article and Find Full Text PDF

The association of necrosis in tumors with poor prognosis implies a potential tumor-promoting role. However, the mechanisms underlying cell death in this context and how damaged tissue contributes to tumor progression remain unclear. Here, we identified p38 mitogen-activated protein kinases (p38 MAPK, a.

View Article and Find Full Text PDF

TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World Study.

Cancer Med

January 2025

Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: The 2021 WHO Classification of Central Nervous System Tumors introduces more molecular markers for glioma reclassification, including TERT promoter (TERTp) mutation as a key feature in glioblastoma diagnosis.

Aims: Given the changes in the entities included in each subtype under the new classification, this research investigated the distribution, prognostic value, and correlations with other molecular alterations of TERTp mutation in different subgroups under this latest classification.

Methods: All glioma patients admitted to Peking Union Medical College Hospital for surgical resection or biopsy from 2011 to 2022 were included.

View Article and Find Full Text PDF

Development and Validation of a Prognostic Molecular Phenotype and Clinical Characterization in Grade III Diffuse Gliomas Treatment with Radio-Chemotherapy.

Ther Clin Risk Manag

January 2025

Department of Oncology, Gaoxin Branch of the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Background: The relationship between molecular phenotype and prognosis in high-grade gliomas (WHO III and IV, HGG) treated with radiotherapy and chemotherapy is not fully understood and needs further exploration.

Methods: The HGG patients following surgery and treatment with radiotherapy and chemotherapy. Univariate and multivariate Cox analyses were used to assess the independent prognostic factors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!